Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Eur J Clin Nutr ; 68(10): 1168-74, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25005677

RESUMEN

BACKGROUND/OBJECTIVES: Inflammation is a central process responsible for health outcomes among surgical patients. Immunonutrition has been investigated as a promising modifying factor; however, inflammatory properties of habitual diet have not yet been investigated. The purpose of this study was to describe inflammatory properties of diet measured by the dietary inflammatory index (DII) among surgical patients treated for colorectal cancer and to link inflammatory properties of habitual diet with a duration of hospitalization. SUBJECTS/METHODS: A follow-up study among colorectal cancer patients treated surgically was performed in Krakow, Poland. In total, 689 patients were recruited for the study. Habitual diet was assessed using a standardized semiquantitative food frequency questionnaire. Overall, 23 dietary items (including macro-and micronutrients) were used to calculate individuals' DII. Gender, age, marital status, body mass index, smoking status, lifetime physical activity, taking vitamin supplements, number of chronic diseases, cancer site, Duke's staging and surgery type were considered as potential covariates. RESULTS: Participants were aged 58 years, with the average hospitalization time of 11 days. Higher DII (meaning diet with higher anti-inflammatory properties) was negatively associated with the duration of hospitalization (univariable linear regression: b=-0.59; P=0.005). Multivariable logistic regression has shown the decrease of the risk of longer stays (>7 days) among patients with the DII >-4.25, but only among younger (⩽60 years) patients, irrespective of Duke's staging. CONCLUSIONS: The DII might be used as a potential predictor of longer hospitalization among colorectal cancer patients treated surgically. The study provides evidence for the role of dietary-related low-grade inflammation among surgical patients.


Asunto(s)
Neoplasias Colorrectales/cirugía , Dieta/efectos adversos , Inflamación/etiología , Tiempo de Internación , Anciano , Conducta Alimentaria , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Polonia
2.
Acta Chir Belg ; 107(3): 297-301, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17685257

RESUMEN

OBJECTIVE: to analyze clinical effectivity of chemotherapy based on Irinotecan, 5-Fluorouracyl and Folinic acid in patients with colorectal carcinoma. METHODS: prospective, randomized, open-label trial in group of 204 patients with advanced colorectal cancer randomized to either chemotherapy with irinotecan+5-FU+leucovorin or supportive care alone (control group) between January 1999--January 2005 was performed. Efficacy and safety of treatment was analysed. RESULTS: Administration of the irinotecan, 5FU, LV regimen to patients with stages II and III significantly improved 5-year survival (81% versus 66% and 66% versus 38%, respectively; p < 0.05). Palliative chemotherapy improved survivals also in stage IV, four patients survived 5 years. Adverse event occurred in 44 of 102 patients (43.1%). CONCLUSIONS: study confirms benefits of irinotecan chemotherapy administered to patients with advanced colorectal cancer. Preliminary data suggests that this chemotherapy regimen should be considered for first-line therapy in the adjuvant and palliative treatment of advanced colorectal cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Camptotecina/análogos & derivados , Neoplasias Colorrectales/tratamiento farmacológico , Fluorouracilo/administración & dosificación , Leucovorina/administración & dosificación , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Camptotecina/administración & dosificación , Camptotecina/efectos adversos , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/patología , Femenino , Fluorouracilo/efectos adversos , Estudios de Seguimiento , Humanos , Irinotecán , Leucovorina/efectos adversos , Masculino , Estadificación de Neoplasias , Cuidados Paliativos , Estudios Prospectivos , Tasa de Supervivencia
3.
Acta Chir Belg ; 105(2): 175-9, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15906909

RESUMEN

BACKGROUND & AIM: To analyze the clinical impact and cost-effectiveness of parenteral immunonutrition (PN). METHODS: Prospective clinical trial of a group of 105 patients operated on for gastric carcinoma between 2001-2003. During the postoperative period, patients were randomly allocated to one of three groups: standard PN (A), PN + glutamine (B) and PN + omega-3-FA (C). The rate and type of complications, hepatic and renal function, cost and treatment tolerance in all groups were analyzed. RESULTS: Postoperative complications were observed in 11 patients (36.6%) in group A, in 7 (23.3%) in B and in 8 (26.6%) in C. The most common complication was pneumonia. Prealbumin concentration and TLC increased faster in groups B and C. The length of hospital stay was significantly shorter in the immunonutrition groups. The cost of PN was highest in C group, while cost of hospital stay was longer in A. CONCLUSIONS: Immunostimulating parenteral nutrition helps to reduce the number of infectious complications, improves the function of the immune system, and has no influence on surgical complications, hepatic and renal function and protein synthesis. The cost of immunostimulating treatment based on omega-3-unsaturated fatty acids is higher than standard.


Asunto(s)
Carcinoma/cirugía , Ácidos Grasos Omega-3/uso terapéutico , Glutamina/uso terapéutico , Desnutrición/terapia , Nutrición Parenteral/métodos , Neoplasias Gástricas/cirugía , Carcinoma/patología , Suplementos Dietéticos , Femenino , Estudios de Seguimiento , Gastrectomía/métodos , Humanos , Masculino , Desnutrición/diagnóstico , Necesidades Nutricionales , Periodo Posoperatorio , Estudios Prospectivos , Medición de Riesgo , Neoplasias Gástricas/patología , Resultado del Tratamiento
5.
Przegl Lek ; 57 Suppl 5: 9-13, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11202309

RESUMEN

BACKGROUND: Poland is among the countries with the high morbidity and mortality rates for gastric carcinoma (GC). The differences of GC biology depending on the geographical regions were suggested. In the literature, there are no reports from detailed clinicopathologic studies carried out in large series of GC patients in Poland. METHODS: Based on the prospectively collected data of 3696 GC patient treated surgically between 1977-1999, potentially significant prognostic factors were analyzed to assess their prognostic value, and their time related distribution during the over 20-year period of the study. RESULTS: The mean age of the patients was 59.0 (SD 11.6) years and ranged from 20 to 93 years. The male-to-female ratio was 2.3. Overall cumulative 5-year survival was 0.28 (for early GC 0.85) and significantly increased over the period of study. Among factors analyzed the depth of invasion, lymph nodes status, tumor size, age, UICC-R classification and rate of involved to removed lymph nodes are of statistically significant and most important prognostic value. In the over 20-year period of study the rate of diffuse type carcinoma acc. to Lauren increased but the tumor locations did not changed significantly. The rate of early GC did not change throughout the period of study but number of most advanced cases decreased. Chemo- and chemotherapy improved outcomes in some groups of patients. CONCLUSIONS: The basic clinicopathologic profile of Polish patients is similar to the reported in Western Europe and Japan, except for significantly higher early GC occurrence in Japan. According to the obtained results the prognosis of GC depends clearly upon the stage of the disease at the time of surgery. The improvement of outcomes during over 20 years of GC study in Poland was due to introducing better diagnosis and routine multimodal treatment.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma/terapia , Gastrectomía/métodos , Neoplasias Gástricas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Vacuna BCG/administración & dosificación , Carcinoma/mortalidad , Carcinoma/patología , Carcinoma/secundario , Quimioterapia Adyuvante , Cisplatino/administración & dosificación , Doxorrubicina/administración & dosificación , Etopósido/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Escisión del Ganglio Linfático , Metástasis Linfática , Masculino , Persona de Mediana Edad , Mitomicina/administración & dosificación , Estadificación de Neoplasias , Proyectos Piloto , Pronóstico , Estudios Prospectivos , Neoplasias Gástricas/mortalidad , Neoplasias Gástricas/patología , Tasa de Supervivencia
6.
Int Arch Allergy Immunol ; 112(2): 125-32, 1997 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9030091

RESUMEN

The sensitizing properties of different complex salts of platinum were defined in vivo by means of the popliteal lymph node (PLN) assay in mice. Hexa- and tetrachloroplatinates were confirmed to be highly immunogenic, inducing vigorous primary immune responses in the draining PLN following single subcutaneous injections. Flow-cytometric analysis revealed a dramatic increase in the total number of cells expressing proliferating cell nuclear antigen. The majority of these cells were of the T helper phenotype (CD4+) reflecting the T-cell dependence of the PLN response induced by Pt salts such as Na2[PtCl6] or Na2[PtCl4]. In contrast, [Pt(NH3)4]Cl2 failed to elicit a significant increase in PLN cell proliferation when compared with saline-treated controls. The differential immunogenicity of the Pt compounds found in vivo directly correlated with their capacity to modulate mechanisms of receptor-mediated endocytosis in murine Langerhans cells in vitro. The reactivity of Na2[PtCl6] or Na2[PtCl4] resembled that of potent contact sensitizers in this endocytosis assay whereas [Pt(NH3)4]Cl2 proved to be mert. These results suggest that [Pt(NH3)4]Cl2 might be less harmful to humans than hexa- or tetrachloroplatinates. As demonstrated with Pt compounds, monitoring of direct effects of low-molecular-weight chemicals on antigen-presenting dendritic cells in vitro is able to predict their sensitizing potential in vivo.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Endocitosis/efectos de los fármacos , Compuestos de Platino/farmacología , Animales , Cloruros/inmunología , Cloruros/farmacología , Cloruros/toxicidad , Cisplatino/análogos & derivados , Cisplatino/inmunología , Cisplatino/farmacología , Cisplatino/toxicidad , Dermatitis Profesional/etiología , Humanos , Hipersensibilidad Inmediata/etiología , Pruebas Inmunológicas , Técnicas In Vitro , Ganglios Linfáticos/citología , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/inmunología , Activación de Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Compuestos de Platino/inmunología , Compuestos de Platino/toxicidad , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología
7.
Anticancer Res ; 8(6): 1423-7, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-3064717

RESUMEN

Three hundred and twenty-two patients with locally advanced (stages III and IVA) and disseminated (stage IVB) gastric cancer were included in a randomized trial to assess the effect of immunochemotherapy (BCG and 5-fluorouracil,5-FU). The survival of patients receiving chemoimmunotherapy was compared to chemotherapy (5-FU) or no further treatment (control) groups. Patients with stage III underwent radical surgery (subtotal or total resection), stage IVA palliative resection, while explorative laparotomy or bypass was performed in stage IVB. Patients with stage III and IVA receiving immunochemotherapy had significantly (p less than 0.05) prolonged survival in comparison to chemotherapy or control groups. Prolongation of survival was more pronounced in patients with diffuse type carcinoma than in patients with intestinal type of tumour according to Lauren's classification. The survival of patients receiving chemotherapy was somewhat shorter than that of the control group, but the differences were not statistically significant. There was no effect of either immunochemotherapy or chemotherapy in patients with stage IVB. No serious side effects of immunochemotherapy were noted. These results indicate that immunochemotherapy may be a safe form of adjuvant treatment in patients with operable gastric cancer.


Asunto(s)
Fluorouracilo/uso terapéutico , Inmunoterapia , Mycobacterium bovis , Neoplasias Gástricas/terapia , Adulto , Anciano , Ensayos Clínicos como Asunto , Terapia Combinada , Esquema de Medicación , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Distribución Aleatoria , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía
9.
Hear Res ; 16(2): 161-7, 1984 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-6526747

RESUMEN

The acoustic startle response (ASR) was elicited with tone pips in sensorineural hearing-impaired DBA/2 mice and in non-impaired C57BL/6 mice. The influence of stimulus frequency and intensity on ASR amplitude varied as a function of both strain and age. Previous neurophysiological findings indicate that ASR amplitude is correlated with the proportion of neurons in the cochlear nucleus and inferior colliculus that respond to the ASR stimulus frequencies and to the excitability of neurons in these structures. ASR amplitude is not highly correlated with threshold sensitivity. These observations suggest several neural correlates of ASR amplitude and have implications regarding central neuronal response properties associated with sensorineural hearing loss.


Asunto(s)
Pérdida Auditiva Sensorineural/fisiopatología , Ratones Endogámicos C57BL/genética , Ratones Endogámicos DBA/genética , Neuronas/fisiología , Reflejo de Sobresalto/fisiología , Estimulación Acústica , Factores de Edad , Animales , Umbral Auditivo , Cóclea/fisiopatología , Pérdida Auditiva Sensorineural/genética , Colículos Inferiores/fisiopatología , Ratones , Convulsiones/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA